Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer.

Simmer F, Venderbosch S, Dijkstra JR, Vink-Börger EM, Faber C, Mekenkamp LJ, Koopman M, De Haan AF, Punt CJ, Nagtegaal ID.

Oncotarget. 2015 Sep 8;6(26):22996-3007.

2.

EMAST is associated with a poor prognosis in microsatellite instable metastatic colorectal cancer.

Venderbosch S, van Lent-van Vliet S, de Haan AF, Ligtenberg MJ, Goossens M, Punt CJ, Koopman M, Nagtegaal ID.

PLoS One. 2015 Apr 17;10(4):e0124538. doi: 10.1371/journal.pone.0124538. eCollection 2015.

3.

Mitochondrial microsatellite instability in patients with metastatic colorectal cancer.

Venderbosch S, van Vliet S, Craenmehr MH, Simmer F, de Haan AF, Punt CJ, Koopman M, Nagtegaal ID.

Virchows Arch. 2015 May;466(5):495-502. doi: 10.1007/s00428-015-1733-8. Epub 2015 Feb 20.

4.

Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.

Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, Kaplan R, Quirke P, Seymour MT, Richman SD, Meijer GA, Ylstra B, Heideman DA, de Haan AF, Punt CJ, Koopman M.

Clin Cancer Res. 2014 Oct 15;20(20):5322-30. doi: 10.1158/1078-0432.CCR-14-0332. Epub 2014 Aug 19.

5.

Sex differences in the timing of identification among children and adults with autism spectrum disorders.

Begeer S, Mandell D, Wijnker-Holmes B, Venderbosch S, Rem D, Stekelenburg F, Koot HM.

J Autism Dev Disord. 2013 May;43(5):1151-6. doi: 10.1007/s10803-012-1656-z.

PMID:
23001766
6.

Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).

Venderbosch S, Doornebal J, Teerenstra S, Lemmens W, Punt CJ, Koopman M.

Acta Oncol. 2012 Sep;51(7):831-9. doi: 10.3109/0284186X.2012.699193. Epub 2012 Jul 16.

PMID:
22794910
7.

Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer.

Mekenkamp LJ, Heesterbeek KJ, Koopman M, Tol J, Teerenstra S, Venderbosch S, Punt CJ, Nagtegaal ID.

Eur J Cancer. 2012 Mar;48(4):501-9. doi: 10.1016/j.ejca.2011.12.004. Epub 2012 Jan 4.

PMID:
22226571
8.

Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature.

Venderbosch S, de Wilt JH, Teerenstra S, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Mol L, Punt CJ, Koopman M.

Ann Surg Oncol. 2011 Nov;18(12):3252-60. doi: 10.1245/s10434-011-1951-5. Epub 2011 Aug 6.

9.

A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?

Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH, Punt CJ.

Eur J Cancer. 2009 Jul;45(11):1935-49. doi: 10.1016/j.ejca.2009.04.023. Epub 2009 May 25. Review.

PMID:
19473832
10.

Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.

Koopman M, Venderbosch S, van Tinteren H, Ligtenberg MJ, Nagtegaal I, Van Krieken JH, Punt CJ.

Eur J Cancer. 2009 Jul;45(11):1999-2006. doi: 10.1016/j.ejca.2009.04.017. Epub 2009 May 18.

PMID:
19457654
11.

Supplemental Content

Loading ...
Support Center